Phase I/II trial of 2 different dose schedules of IMMU 130.
Phase of Trial: Phase I/II
Latest Information Update: 15 Sep 2013
Price : $35 *
At a glance
- Drugs Labetuzumab govitecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 15 Sep 2013 This trial is expected to start in the first quarter of 2014, according to an Immunomedics media release.
- 15 Sep 2013 New trial record